ArticleJournal of general internal medicine2024
Determinants of Plasma Alzheimer's Disease Biomarker Use by Primary Care Providers and Dementia Specialists.
Article in Journal of general internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Adoption of Alzheimer's disease biomarkers by primary care clinicians: findings from the National Dementia Workforce Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Factors influencing implementation of an Alzheimer's disease blood test among UK old age psychiatrists: mixed-methods study using the theoretical domains framework.Age and ageing · 2026Article
- Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers.Clinical interventions in aging · 2026Review
- Proceedings of the Alzheimer's Diagnosis in Older Adults With Chronic Conditions Network Inaugural Annual Conference.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Paving the way for Alzheimer's disease blood-based biomarkers in primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Applying recommendations for diagnostic disclosure of mild cognitive impairment and dementia: Practical guidance for clinicians.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Observational
- Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature.Alzheimer's & dementia (Amsterdam, Netherlands)Review
- Older US adults' experiences with and views about cognitive screening and blood biomarker testing for Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).Alzheimer's & dementia (New York, N. Y.)Article
- Blood-based biomarkers for Alzheimer's disease in primary care: A French qualitative study exploring perspectives of general practitioners.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- General practitioners' perspectives on blood biomarkers for Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe efficiencies of plasma Alzheimer's disease (AD) biomarkers could facilitate early AD diagnosis. Unfortunately, limited knowledge exists about whether and how they would be used by clinicians.
objectiveTo identify and compare determinants of plasma AD biomarker use reported by primary care providers and dementia specialists.
designSemi-structured interviews with clinicians organized using Rogers' Diffusion of Innovations theory and analyzed using an iterative coding approach.
participantsThe subjects were internal and family medicine, neurology, and geriatrics providers with varying degrees of expertise in dementia diagnosis and care. MAIN MEASURES: Factors influencing a clinician's decision to use or not use plasma AD biomarkers in clinical practice. KEY
resultsWe interviewed 30 clinicians (16 family or internal medicine providers, 8 geriatricians, and 6 neurologists). Fifteen were dementia specialists. Hesitance to use plasma AD biomarkers was due to perceived lack of effective treatments for AD, limited access to supports, and stigma. Plasma AD biomarkers would be more readily adopted by clinicians with dementia expertise.
conclusionsSeveral factors will influence clinical use of plasma AD biomarkers. Some of them may inform the design of interventions to promote the effective and appropriate clinical translation of these tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.